GenMark Diagnostic
GenMark Diagnostics is a publicly traded molecular diagnostics company (NASDAQ: GNMK) that develops and commercializes multiplex clinical tests based on its proprietary electrochemical sensor detection technology, serving hospital and reference laboratory customers.
- Company typePrivate
- Founded2010
- HeadquartersCarlsbad, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What GenMark Diagnostic does
GenMark Diagnostics is a publicly traded molecular diagnostics company (NASDAQ: GNMK), founded in 2010 and headquartered in Carlsbad, California. The company focuses on developing and commercializing multiplex molecular diagnostic tests built around its proprietary electrochemical sensor detection technology, addressing clinical customers such as hospital laboratories and reference labs that require rapid, sample-to-answer molecular results for infectious disease and other indications.
The company operates at commercial scale, with a workforce in the 501–1,000 employee range and a public-market capital structure. Its disclosed funding history — a $40M growth round led by GE Capital in January 2015, a non-dilutive BARDA award in March 2020, and a $70M financing in May 2020 — indicates active platform commercialization alongside federal-pandemic engagement in 2020. Product, pricing, channel, and detailed portfolio information was not available at the time of analysis because the company's primary website (genmarkdx.com) was inaccessible (Cloudflare 522 connection-timeout error), preventing direct documentation of the assay menu, instrument footprint, and go-to-market mechanics.
GenMark's revenue model in the clinical molecular diagnostics sector is anchored on instrument placements in hospital and reference-lab settings plus recurring consumable (assay cartridge) revenue per test. Public-company scale, the BARDA relationship, and the size of the recent equity raise suggest a franchise with meaningful installed-base economics, though precise revenue figures, customer logos, and segment mix were not contained in the source material. Leadership comprises a Chief Executive Officer (Tanya Monga), a CFO (Paul Ross), and a Founder/President (Scott Mendel), reflecting a founder-influenced management structure typical of venture-backed diagnostics companies that transitioned to public-market status.
GenMark Diagnostic firmographics
Firmographics- Name
- GenMark Diagnostic
- Website
- https://genmarkdx.com
- Company type
- Private
- Founded year
- 2010
- Headcount range
- 501–1,000 employees
- Short description
- GenMark Diagnostics is a publicly traded molecular diagnostics company (NASDAQ: GNMK) that develops and commercializes multiplex clinical tests based on its proprietary electrochemical sensor detection technology, serving hospital and reference laboratory customers.
- Ownership category
- akta.pro rank
GenMark Diagnostic industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
Keywords
Where GenMark Diagnostic is headquartered
LocationHeadquarters
- HQ city
- Carlsbad
- HQ country
- United States
- HQ region
- North America
Markets served
GenMark Diagnostic business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GenMark Diagnostic product offering
Product offeringCore offering
GenMark Diagnostic is a molecular diagnostics company focused on developing and commercializing its proprietary sensor detection technology for clinical diagnostic applications. The company builds multiplex molecular diagnostic testing systems and consumables used by hospital and reference laboratories for the detection of pathogens and genetic targets from patient samples.
Product overview
GenMark Diagnostic is a molecular diagnostics company. Based on the available source data, the company's website (genmarkdx.com) was inaccessible at the time of data collection (Connection timed out - Error 522). No product, service, or portfolio information was available from the aggregated sources to populate product details.
Differentiator
Problem solved
Functional benefit
Companies that use GenMark Diagnostic
Customer profileIdeal customer profiles2 records
GenMark Diagnostic technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
GenMark Diagnostic partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
GenMark Diagnostic competitors and assessment
Company assessmentBroad incumbents
- Cepheid: Cepheid (a Danaher subsidiary) markets the GeneXpert molecular diagnostic system for syndromic infectious disease testing, directly competing with GenMark's ePlex in hospital labs. Comparable on platform breadth, target customer (clinical/hospital labs), and assay menu.
- Hologic: Hologic operates the Panther / Panther Fusion molecular diagnostics platforms and diagnostics business. Same broad diagnostic customer base (clinical labs, hospitals) and molecular diagnostics category as GenMark, though Hologic is a much larger diversified medtech.
- Becton Dickinson (BD): BD's Diagnostic Systems business includes the BD MAX and BD COR molecular platforms as well as the BD Veritor rapid diagnostics. Direct overlap with GenMark in hospital molecular testing menus and customer segments.
- DiaSorin: DiaSorin (through its Luminex acquisition) offers multiplex molecular diagnostic platforms (NxTAG, xMAP, ARIES), overlapping with GenMark's syndromic testing focus. Comparable as a broader IVD platform business with molecular diagnostics exposure.
- Roche Diagnostics: Roche operates cobas Liat, cobas 6800/8800, and MagNA Pure molecular systems, dominating core lab molecular diagnostics. Same end customers (hospital/clinical labs) and assay menus as GenMark, though at much larger scale and broader menu coverage.
Direct peers
- BioFire Diagnostics: BioFire (owned by bioMérieux) is the maker of the FilmArray multiplex PCR system, the dominant syndromic molecular diagnostic platform used in hospitals. Direct competitor to GenMark's ePlex across respiratory, bloodstream, GI, and meningitis/encephalitis panels.
- QuidelOrtho: QuidelOrtho develops and commercializes molecular diagnostics (Savanna, Solana, Lyra product lines) and rapid immunoassay tests. Competes with GenMark for clinical lab customers and offers partially overlapping respiratory infectious disease assays.
Emerging players
- Accelerate Diagnostics: Accelerate Diagnostics develops rapid molecular and phenotypic diagnostics for bloodstream infections, an area where GenMark's bloodstream infection ePlex panel competes. Both target infectious disease diagnostics through novel non-traditional molecular chemistries.
- T2 Biosystems: T2 Biosystems develops molecular diagnostic tests for sepsis and other bloodstream infections using T2MR technology. Targeted overlap with GenMark on bloodstream infection diagnostics and similar small-cap public molecular diagnostics profile.
- Mesa Labs: Mesa Labs, through its BioDot and other acquisitions, plays in adjacent rapid diagnostics and life science measurement, offering a comparable small- to mid-cap IVD profile and order-of-magnitude scale similar to GenMark.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key highlights7 records
Customer concentration
GenMark Diagnostic social profiles
Digital presenceGenMark Diagnostic financial estimates
Financial estimateRevenue estimate
Valuation estimate
GenMark Diagnostic leadership team
Management profileNumber of profiles
Profiles3 records
GenMark Diagnostic funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GenMark Diagnostic M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GenMark Diagnostic
What does GenMark Diagnostic do?
GenMark Diagnostic is a molecular diagnostics company focused on developing and commercializing its proprietary sensor detection technology for clinical diagnostic applications. The company builds multiplex molecular diagnostic testing systems and consumables used by hospital and reference laboratories for the detection of pathogens and genetic targets from patient samples.
When was GenMark Diagnostic founded?
GenMark Diagnostic was founded in 2010. It employs 501 to 1,000 people.
Where is GenMark Diagnostic based?
GenMark Diagnostic is headquartered in Carlsbad, United States, in the North America region.
Who are GenMark Diagnostic's main competitors?
Broad incumbents on record are Cepheid, Hologic, Becton Dickinson (BD), DiaSorin and Roche Diagnostics. Direct peers are BioFire Diagnostics and QuidelOrtho. Emerging players are Accelerate Diagnostics, T2 Biosystems and Mesa Labs.
Does GenMark Diagnostic have an API?
No public API is recorded for GenMark Diagnostic.
What industry is GenMark Diagnostic in?
GenMark Diagnostic's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 621511 and its SIC code is 2835.